About Allomek Therapeutics
Allomek Therapeutics is a company based in Farmington (United States) founded in 2010 was acquired by Pasithea in October 2022. Allomek Therapeutics has raised $1.76 million across 3 funding rounds from investors including Pasithea and Connecticut Innovations. Allomek Therapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Farmington, United States
- SectorsHealthcare
- Email••••••••
- Website allomek.com
- Social LinkedIn
- Acquired by Pasithea (Oct 2022)
Funding Insights of Allomek Therapeutics
Allomek Therapeutics has successfully raised a total of $1.76M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $1.31 million completed in February 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.76M
- Total Rounds 3
- Last Round Seed — $1.31M
- First Round $150,000
(May 2013)
- Investors Count 1
All 3 funding rounds of Allomek Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2020 | $1.31M | Seed | – | – | – |
| Feb 2017 | $300,000 | Seed | – | – | – |
| May 2013 | $150,000 | Seed | – | – |
2 investors in total: 2 institutional.
Investors in Allomek Therapeutics
Allomek Therapeutics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Pasithea and Connecticut Innovations.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital services for biotech, IT, and innovative sectors in Connecticut. | – | ctinnovations.com | - | |
Pasithea is focused on developing treatments for neurological disorders. | 2020 | pasithea.com | Miami Beach, United States |
Investor details for Allomek Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Allomek Therapeutics
4 dated milestones of Allomek Therapeutics across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Allomek Therapeutics is founded.
- Funding First funding round of $150K.
- Funding Latest funding round, Seed, of $1.3M.
- Exit Acquired by Pasithea.
Competitors of Allomek Therapeutics
Allomek Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| adacap.com | 2002 | Saint Genis Pouilly, France | $56.13M | – | Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. |
Detailed competitors of Allomek Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Allomek Therapeutics
Complete news archive for Allomek Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Allomek Therapeutics
10 companies that operate in the same segment as Allomek Therapeutics (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Allomek Therapeutics
Allomek Therapeutics was founded in 2010 and raised its 1st funding round 3 years after it was founded.
Allomek Therapeutics is headquartered in Farmington, United States.
Allomek Therapeutics is a funded company, having raised a total of $1.76M across 3 funding rounds to date. The company's 1st funding round was a Seed of $150K, raised on May 2013.
Allomek Therapeutics was founded in 2010 and is based in Farmington, United States. Operations are conducted virtually through partnerships with contract research organizations. Focus is placed on the development of allosteric MEK inhibitors as targeted small molecule therapeutics for oncology. Preclinical testing is underway for multiple cancer indications, with emphasis on precision approaches in the biotechnology sector.
Allomek Therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Allomek Therapeutics has 2 investors. Key investors include Pasithea, and Connecticut Innovations.
Yes. Allomek Therapeutics was acquired by Pasithea in October 2022.